In partnership with

See this week's breakthrough USPTO patent grants!

Stay up-to-date with AI

The Rundown is the most trusted AI newsletter in the world, with 1,000,000+ readers and exclusive interviews with AI leaders like Mark Zuckerberg, Demis Hassibis, Mustafa Suleyman, and more.

Their expert research team spends all day learning what’s new in AI and talking with industry experts, then distills the most important developments into one free email every morning.

Plus, complete the quiz after signing up and they’ll recommend the best AI tools, guides, and courses – tailored to your needs.

Sign up to start learning.

Table of Contents

• This Week's Patent News

• Weekly Statistics

• Main Article

• Trivia (question)

• Featured Inventor

• Today in Patent History

• Our Features

• Centurion Patentors

• Trivia (answer)

• Recommendations

This Week's Patent News:

1. Pfizer and BioNTech Succeed in Invalidating Moderna's COVID-19 Vaccine Patents. On March 5, 2025, Pfizer and BioNTech convinced the U.S. Patent Office tribunal to invalidate two of Moderna's COVID-19 vaccine patents. The decision was based on prior art indicating that the inventions were known before Moderna patented them.

2. Merck's New Version of Keytruda Faces Patent Dispute with Halozyme Therapeutics. Merck & Co. is facing a patent dispute with Halozyme Therapeutics over an enzyme used in a new injectable version of its cancer drug, Keytruda. This enzyme allows Keytruda to be administered by injection rather than intravenously.

3. USPTO's First-Time Filer Expedited Examination Pilot Program Set to Expire. The USPTO announced that its First-Time Filer Expedited Examination Pilot Program will expire as scheduled on March 11, 2025. This program offered eligible first-time filers expedited initial written feedback on their applications.

4. Federal Circuit Rules on Diamond Compact Patent Validity. The Federal Circuit ruled that claims directed to a polycrystalline diamond compact (PDC) are not abstract under § 101, impacting chemical and materials patent practitioners.

5. Teva Plans to Seek Supreme Court Review Over Drug-Patent Listings. Teva Pharmaceutical Industries Ltd. announced plans to ask the U.S. Supreme Court to review issues related to drug-patent listings, following proceedings in the U.S. Court of Appeals for the Federal Circuit.

Initially developed for space-age safety, memory foam’s remarkable ability to contour to pressure and return to its original shape soon found a less glamorous but highly impactful second life: mattresses. In the 1990s, companies like Tempur-Pedic saw the terrestrial potential of this technology, bringing space-age comfort to bedrooms worldwide. The compressed foam mattress, however, elevated this concept to a logistical marvel. By harnessing foam's flexibility, manufacturers developed a way to vacuum-seal and roll mattresses into manageable, box-sized parcels, a feat of engineering that would make even NASA proud.

Utility-wise, the compressed foam mattress is a modern marvel. It delivers ergonomic support, relieves pressure points, and, most importantly, ships directly to your doorstep, sparing you the indignity of wrestling a mattress onto the roof of your car. Whether recovering from a marathon or simply battling the existential weight of adulthood, this mattress cradles you like the overachieving cocoon it is.

Thanks to Yost and a dash of ingenuity, we are all one step closer to achieving a universal dream: a good night's sleep.

Please scroll to the bottom of this newsletter to find out.

Renowned for his adaptability and ingenuity, Sergey thrives in tackling unfamiliar technical challenges and navigating uncertainty with a deep understanding of system-level impacts. His collaborative mindset and ability to influence cross-functional teams have been instrumental in solving intricate problems and driving organizational success.

Gorobets is listed as the 25th most prolific inventor in the UK, holding 167 patents across various fields. His ability to adapt to new challenges and collaborate across disciplines has made him a notable figure in engineering and innovation.

Congratulations to last week's Centurion Patentors!
We are excited to welcome the following inventors into these prestigious patent clubs:

For more info about their research & patents, click here

The answer is:

~27.1% of patents since 1976 have never been cited.